Artemis Medicare Falls 12.19%: 7 Key Factors Behind the Sharp Weekly Decline

2 February 2026: Strong Profitability Masks Underlying Concerns

Artemis Medicare Services Ltd opened the week with a closing price of ₹239.40, down 3.21% from the previous close. The company reported a strong Q3 FY26 performance, with operating profit growth at an annualised 82.15% and net profit rising 41.51%. Despite these robust financials, MarketsMOJO downgraded the stock from 'Buy' to 'Hold' citing mixed financial and technical signals. The downgrade reflected concerns over management efficiency, with a modest return on equity of 9.51%, and a technical momentum shift from mildly bullish to sideways.

Technical indicators such as the weekly MACD turned bearish, while the monthly MACD remained mildly bearish. The Relative Strength Index (RSI) was neutral weekly but bullish monthly, indicating some underlying strength despite short-term uncertainty. The stock traded within a wide range, with a 52-week high of ₹335.90 and a low of ₹208.75, highlighting significant volatility.

3 February 2026: Intraday Low Amid Price Pressure

The stock faced intense selling pressure on 3 February, closing at ₹216.90, down 9.40% for the day. It hit an intraday low of ₹220.55, reflecting a 7.87% drop from the prior close. This marked the third consecutive day of decline, with a cumulative loss of 10.73%. Artemis Medicare underperformed its hospital sector peers by 9.73% and traded below all key moving averages, signalling sustained downward momentum.

Despite the broader market’s mixed performance, the Sensex closed up 2.63%, highlighting Artemis Medicare’s relative weakness. The stock’s Mojo Score stood at 54.0 with a 'Hold' grade, reflecting the cautious stance amid volatile trading conditions. The technical positioning below the 5-day to 200-day moving averages suggested limited immediate support for the stock price.

4 February 2026: Mixed Technical Signals and Mild Bullish Shift

On 4 February, Artemis Medicare closed at ₹214.40, down 1.15%. Technical indicators showed a nuanced picture: daily moving averages turned mildly bullish, suggesting potential short-term momentum improvement. However, weekly MACD remained bearish and monthly MACD mildly bearish, indicating ongoing medium- and long-term pressure.

The Relative Strength Index (RSI) readings were bullish on both weekly and monthly timeframes, hinting at emerging strength. Bollinger Bands showed bearish weekly trends but sideways monthly patterns, reflecting elevated volatility and consolidation. The Know Sure Thing (KST) indicator and Dow Theory assessments remained mildly bearish, while On-Balance Volume (OBV) was mixed.

Despite these mixed signals, the stock remained closer to its 52-week low of ₹208.75 than its high of ₹335.00, underscoring recent downward pressure. The Sensex’s resilience contrasted with Artemis Medicare’s ongoing weakness, with the stock’s year-to-date decline at 19.17% versus the Sensex’s 1.74% fall.

5 February 2026: Downgrade to Sell Amid Financial and Technical Deterioration

MarketsMOJO further downgraded Artemis Medicare from 'Hold' to 'Sell' on 5 February, reflecting deteriorating financial trends and weakening technical momentum. The stock closed at ₹216.40, up 0.93% intraday but still down 10.07% for the week. Despite operational strengths such as a half-yearly ROCE of 13.34% and low debt-equity ratio of 0.32, the company’s EPS declined to ₹1.41, the lowest in recent quarters.

Promoter share pledging at 44.53% added to investor concerns. Valuation metrics showed a price-to-book ratio of 3.8 and a PEG ratio of 2.1, suggesting the stock may be somewhat expensive relative to earnings growth. Technical indicators shifted to mildly bearish, with bearish weekly and monthly MACD, KST, and Dow Theory signals. The RSI remained bullish but was insufficient to offset the broader negative momentum.

The stock traded near its 52-week low, with intraday volatility between ₹210.60 and ₹224.70. The Sensex gained 1.79% over the week, further highlighting Artemis Medicare’s underperformance.

6 February 2026: Mild Recovery but Weak Weekly Close

The week ended with a slight recovery as Artemis Medicare closed at ₹217.20, up 0.37% on the day. However, the overall weekly decline remained steep at 12.19%. Technical momentum continued to show caution, with the stock hovering near its 52-week low and mixed signals from key indicators. The weekly MACD remained bearish, while the RSI retained a bullish stance, reflecting ongoing uncertainty.

Volume was subdued at 3,964 shares, indicating limited buying interest. The Sensex closed marginally higher by 0.10%, underscoring Artemis Medicare’s continued underperformance. Investors remain watchful as the stock navigates a challenging technical and fundamental environment.

Key Takeaways

Positive Signals: Artemis Medicare demonstrated strong operational profitability with robust profit growth and a healthy capital structure. The company’s long-term returns remain impressive, with three- and five-year gains far exceeding Sensex benchmarks. The Relative Strength Index (RSI) readings on monthly and weekly charts suggest underlying strength despite short-term volatility.

Cautionary Signals: The stock’s price declined sharply by 12.19% over the week, significantly underperforming the Sensex’s 1.51% gain. Technical momentum shifted from mildly bullish to sideways and then mildly bearish, with bearish MACD, KST, and Dow Theory indicators dominating. Promoter share pledging at 44.53% and a declining EPS raise concerns about near-term risks. The stock traded below all key moving averages, indicating sustained downward pressure.

Investors should note the mixed financial and technical signals, with the recent downgrade to a 'Sell' rating reflecting heightened caution. The stock’s proximity to its 52-week low and ongoing volatility suggest that a clear directional trend has yet to emerge.

Conclusion

Artemis Medicare Services Ltd’s week was characterised by significant price weakness amid mixed fundamental and technical developments. Despite strong profitability and solid long-term returns, the stock faced intense selling pressure, technical momentum deterioration, and multiple downgrades from MarketsMOJO. The divergence between operational strength and market performance highlights investor caution, driven by concerns over management efficiency, promoter pledging, and technical indicators signalling bearish trends.

While some short-term technical signals hint at potential consolidation or mild recovery, the overall outlook remains cautious. Market participants should closely monitor upcoming earnings releases, technical momentum shifts, and volume trends to assess whether Artemis Medicare can stabilise and regain upward momentum in the near term.

Unlock special upgrade rates for a limited period. Start Saving Now →